BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23139259)

  • 1. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
    Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
    Sun PL; Li B; Ye QF
    Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
    Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
    von Moos R; Koeberle D; Schacher S; Hayoz S; Winterhalder RC; Roth A; Bodoky G; Samaras P; Berger MD; Rauch D; Saletti P; Plasswilm L; Zwahlen D; Meier UR; Yan P; Izzo P; Klingbiel D; Bärtschi D; Zaugg K;
    Eur J Cancer; 2018 Jan; 89():82-89. PubMed ID: 29241084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
    Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J;
    Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
    Velenik V; Ocvirk J; Oblak I; Anderluh F
    Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Jensen LH; Lindebjerg J; Ploen J; Hansen TF; Jakobsen A
    Ann Oncol; 2012 Sep; 23(9):2341-2346. PubMed ID: 22367707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer.
    Gao YH; Zhang X; An X; Cai MY; Zeng ZF; Chen G; Kong LH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Strahlenther Onkol; 2014 Feb; 190(2):158-64. PubMed ID: 24408055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.